Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CTXR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CTXR

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Citius Pharmaceuticals Inc

CTXR
Current price
1.60 USD +0.055 USD (+3.57%)
Last closed 1.63 USD
ISIN US17322U2078
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 16 650 005 USD
Yield for 12 month -92.28 %
1Y
3Y
5Y
10Y
15Y
CTXR
21.11.2021 - 28.11.2021

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Address: 11 Commerce Drive, Cranford, NJ, United States, 07016

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.00 USD

P/E Ratio

Dividend Yield

Financials CTXR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CTXR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

+155 926 USD

Current Year

Last Year

-194 316 USD

Current Quarter

Last Quarter

EBITDA -42 983 960 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -25.32 %
PEG Ratio
Return On Equity TTM -60.53 %
Wall Street Target Price 6.00 USD
Revenue TTM
Book Value 6.92 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -5.76 USD
Diluted Eps TTM -5.76 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CTXR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 9.13
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -2.74
Price Book MRQ 0.31

Technical Indicators CTXR

For 52 Weeks

0.65 USD 26.25 USD
50 Day MA 1.07 USD
Shares Short Prior Month 1 348 420
200 Day MA 3.57 USD
Short Ratio 0.27
Shares Short 969 686
Short Percent 12.62 %